Kristian Humer has served as 4DMT's Chief Financial Officer and Principal Financial Officer since November 2025, and as Principal Accounting Officer since March 2026 (appointed by the board on March 25, 2026, succeeding Ashoo Gupta in that role).
Mr. Humer previously served as Chief Financial Officer at Foghorn Therapeutics, Inc. from April 2024 to November 2025. From July 2021 to September 2023, he served as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc. From January 2010 to July 2021, he served in various roles at Citigroup Global Markets Inc., including most recently as Managing Director in the Healthcare Investment Banking Group from December 2016 to July 2021.
Mr. Humer holds an MBA degree from Duke University's Fuqua School of Business and a BA (Hons) degree in Accounting & Economics from the University of Reading.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.